Search

Your search keyword '"Guerrera, Maria L."' showing total 22 results
Start Over Author "Guerrera, Maria L." Publication Year Range Last 10 years
22 results on '"Guerrera, Maria L."'

1. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Author

Castillo, Jorge J., Branagan, Andrew R., Sermer, David, Flynn, Catherine A., Meid, Kirsten, Little, Megan, Stockman, Katherine, White, Timothy, Canning, Alexa, Guerrera, Maria L., Kofides, Amanda, Liu, Shirong, Liu, Xia, Richardson, Kris, Tsakmaklis, Nicholas, Patterson, Christopher J., Hunter, Zachary R., Treon, Steven P., and Sarosiek, Shayna

Published
2024
Full Text
View/download PDF

2. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Author

Castillo, Jorge J., Meid, Kirsten, Gustine, Joshua N., Leventoff, Carly, White, Timothy, Flynn, Catherine A., Sarosiek, Shayna, Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Branagan, Andrew R., O’Donnell, Elizabeth, Raje, Noopur, Yee, Andrew J., Patterson, Christopher J., Hunter, Zachary R., and Treon, Steven P.

Published
2022
Full Text
View/download PDF

5. MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

Author

Treon, Steven P., Gustine, Joshua, Xu, Lian, Manning, Robert J., Tsakmaklis, Nicholas, Demos, Maria, Meid, Kirsten, Guerrera, Maria L., Munshi, Manit, Chan, Gloria, Chen, Jiaji, Kofides, Amanda, Patterson, Christopher J., Yang, Guang, Liu, Xia, Severns, Patricia, Dubeau, Toni, Hunter, Zachary R., and Castillo, Jorge J.

Published
2018
Full Text
View/download PDF

6. Venetoclax in Previously Treated Waldenström Macroglobulinemia

Author

Castillo, Jorge J., primary, Allan, John N., additional, Siddiqi, Tanya, additional, Advani, Ranjana H., additional, Meid, Kirsten, additional, Leventoff, Carly, additional, White, Timothy P., additional, Flynn, Catherine A., additional, Sarosiek, Shayna, additional, Branagan, Andrew R., additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nicholas, additional, Xu, Lian, additional, Yang, Guang, additional, Patterson, Christopher J., additional, Hunter, Zachary R., additional, Davids, Matthew S., additional, Furman, Richard R., additional, and Treon, Steven P., additional

Published
2022
Full Text
View/download PDF

7. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Author

Castillo, Jorge J., primary, Meid, Kirsten, additional, Gustine, Joshua N., additional, Leventoff, Carly, additional, White, Timothy, additional, Flynn, Catherine A., additional, Sarosiek, Shayna, additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nicholas, additional, Xu, Lian, additional, Yang, Guang, additional, Branagan, Andrew R., additional, O’Donnell, Elizabeth, additional, Raje, Noopur, additional, Yee, Andrew J., additional, Patterson, Christopher J., additional, Hunter, Zachary R., additional, and Treon, Steven P., additional

Published
2021
Full Text
View/download PDF

8. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia

Author

Gustine, Joshua N., primary, Xu, Lian, additional, Yang, Guang, additional, Liu, Xia, additional, Kofides, Amanda, additional, Tsakmaklis, Nicholas, additional, Munshi, Manit, additional, Demos, Maria, additional, Guerrera, Maria L., additional, Meid, Kirsten, additional, Patterson, Christopher J., additional, Sarosiek, Shayna, additional, Branagan, Andrew R., additional, Hunter, Zachary R., additional, Castillo, Jorge J., additional, and Treon, Steven P., additional

Published
2021
Full Text
View/download PDF

9. Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

Author

Castillo, Jorge J., primary, Abeykoon, Jithma P., additional, Gustine, Joshua N., additional, Zanwar, Saurabh, additional, Mein, Kirsten, additional, Flynn, Catherine A., additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nickolas, additional, King, Rebecca, additional, Yang, Guang, additional, Hunter, Zachary R., additional, Advani, Ranjana H., additional, Palomba, Maria Lia, additional, Ansell, Stephen M., additional, Gertz, Morie A., additional, Kapoor, Prashant, additional, and Treon, Steven P., additional

Published
2020
Full Text
View/download PDF

10. Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Author

Castillo, Jorge J., primary, Gustine, Joshua N., additional, Meid, Kirsten, additional, Flynn, Catherine A., additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Jimenez, Cristina, additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nicholas, additional, Patterson, Christopher J., additional, Xu, Lian, additional, Yang, Guang, additional, Hunter, Zachary R., additional, and Treon, Steven P., additional

Published
2020
Full Text
View/download PDF

11. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

Author

Castillo, Jorge J., primary, Itchaki, Gilad, additional, Gustine, Joshua N., additional, Meid, Kirsten, additional, Flynn, Catherine A., additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Jimenez, Cristina, additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nicholas, additional, Patterson, Christopher J., additional, Xu, Lian, additional, Yang, Guang, additional, Hunter, Zachary R., additional, and Treon, Steven P., additional

Published
2020
Full Text
View/download PDF

12. CXCR4 mutational status does not impact outcomes in patients with W aldenström macroglobulinemia treated with proteasome inhibitors

Author

Castillo, Jorge J., primary, Gustine, Joshua N., additional, Meid, Kirsten, additional, Flynn, Catherine A., additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Jimenez, Cristina, additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nicholas, additional, Patterson, Christopher J., additional, Xu, Lian, additional, Yang, Guang, additional, Hunter, Zachary R., additional, and Treon, Steven P., additional

Published
2020
Full Text
View/download PDF

13. Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

Author

Castillo, Jorge J., primary, Gustine, Joshua N., additional, Keezer, Andrew, additional, Meid, Kirsten, additional, Flynn, Catherine A., additional, Dubeau, Toni E., additional, Chan, Gloria, additional, Chen, Jiaji, additional, Demos, Maria G., additional, Guerrera, Maria L., additional, Jimenez, Cristina, additional, Kofides, Amanda, additional, Liu, Xia, additional, Munshi, Manit, additional, Tsakmaklis, Nicholas, additional, Patterson, Christopher J., additional, Xu, Lian, additional, Yang, Guang, additional, Hunter, Zachary R., additional, and Treon, Steven P., additional

Published
2020
Full Text
View/download PDF

14. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

Author

Castillo, Jorge J., primary, Xu, Lian, additional, Gustine, Joshua N., additional, Keezer, Andrew, additional, Meid, Kirsten, additional, Dubeau, Toni E., additional, Liu, Xia, additional, Demos, Maria G., additional, Kofides, Amanda, additional, Tsakmaklis, Nicholas, additional, Chen, Jiaji G., additional, Munshi, Manit, additional, Guerrera, Maria L., additional, Chan, Gloria G., additional, Patterson, Christopher J., additional, Yang, Guang, additional, Hunter, Zachary R., additional, and Treon, Steven P., additional

Published
2019
Full Text
View/download PDF

15. Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.

Author

Castillo, Jorge J., Abeykoon, Jithma P., Gustine, Joshua N., Zanwar, Saurabh, Mein, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nickolas, King, Rebecca, Yang, Guang, Hunter, Zachary R., Advani, Ranjana H., Palomba, Maria Lia, Ansell, Stephen M., Gertz, Morie A., and Kapoor, Prashant

Subjects
PROGRESSION-free survival, PROTEIN-tyrosine kinases, KINASE inhibitors, MULTIVARIATE analysis, CLINICAL trials
Abstract

Summary: Ibrutinib is associated with durable responses in patients with Waldenström macroglobulinaemia (WM). We hypothesized that response depth is predictive of progression‐free survival (PFS) in WM patients treated with ibrutinib. Using landmark analyses, we evaluated response depth in two cohorts of WM patients treated with ibrutinib monotherapy. The learning cohort was composed of 93 participants from two clinical trials, and the validation cohort of 190 consecutive patients treated off clinical trial. Rates of partial response (PR) or better at six months in learning and validation cohorts were 64% and 71% respectively (P = 0·29). In the learning cohort, three‐year PFS rates for patients who attained PR or better at six months versus not were 81% and 57% respectively (P = 0·009). In the validation cohort, three‐year PFS rates for patients who attained PR or better at six months versus not were 83% and 54% respectively (P = 0·008). In multivariate analyses, attaining PR or better at six months was associated with superior PFS in the learning [hazard ratio (HR) 0·38; P = 0·01] and validation cohorts (HR 0·18; P = 0·004). Attaining PR at six months on ibrutinib emerges as an intermediate outcome of interest and should be validated as surrogate for PFS in clinical trials evaluating Bruton tyrosine kinase inhibitors in WM. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. TP53mutations are associated with mutatedMYD88andCXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia

Author

Gustine, Joshua N., primary, Tsakmaklis, Nicholas, additional, Demos, Maria G., additional, Kofides, Amanda, additional, Chen, Jiaji G., additional, Liu, Xia, additional, Munshi, Manit, additional, Guerrera, Maria L., additional, Chan, Gloria G., additional, Patterson, Christopher J., additional, Meid, Kirsten, additional, Dubeau, Toni, additional, Yang, Guang, additional, Hunter, Zachary R., additional, Treon, Steven P., additional, Castillo, Jorge J., additional, and Xu, Lian, additional

Published
2018
Full Text
View/download PDF

18. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

Author

Treon, Steven P., primary, Gustine, Joshua, additional, Xu, Lian, additional, Manning, Robert J., additional, Tsakmaklis, Nicholas, additional, Demos, Maria, additional, Meid, Kirsten, additional, Guerrera, Maria L., additional, Munshi, Manit, additional, Chan, Gloria, additional, Chen, Jiaji, additional, Kofides, Amanda, additional, Patterson, Christopher J., additional, Yang, Guang, additional, Liu, Xia, additional, Severns, Patricia, additional, Dubeau, Toni, additional, Hunter, Zachary R., additional, and Castillo, Jorge J., additional

Published
2017
Full Text
View/download PDF

19. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.

Author

Gustine, Joshua N., Tsakmaklis, Nicholas, Demos, Maria G., Kofides, Amanda, Chen, Jiaji G., Liu, Xia, Munshi, Manit, Guerrera, Maria L., Chan, Gloria G., Patterson, Christopher J., Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R., Treon, Steven P., Castillo, Jorge J., and Xu, Lian

Subjects
GENETIC mutation, CXCR4 receptors, WALDENSTROM'S macroglobulinemia, GENETICS, PROTEIN receptors
Abstract

Summary: Little is known about TP53 mutations in Waldenström Macroglobulinaemia (WM). We evaluated 265 WM patients for TP53 mutations by next‐generation sequencing, and validated the findings by Sanger sequencing. TP53 mutations were identified and validated in 6 (2·6%) patients that impacted the DNA‐binding domain. All six were MYD88‐ and CXCR4‐mutated. Ibrutinib showed activity in patients carrying all three mutations. With a median follow‐up of 18 months, 2 (33%) with biallelic TP53 inactivation died of progressive disease. TP53 mutations are rare in WM, and associate with MYD88 and CXCR4 mutations. WM patients with TP53 mutations show response to ibrutinib. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

20. <italic>MYD88</italic> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.

Author

Treon, Steven P., Gustine, Joshua, Xu, Lian, Manning, Robert J., Tsakmaklis, Nicholas, Demos, Maria, Meid, Kirsten, Guerrera, Maria L., Munshi, Manit, Chan, Gloria, Chen, Jiaji, Kofides, Amanda, Patterson, Christopher J., Yang, Guang, Liu, Xia, Severns, Patricia, Dubeau, Toni, Hunter, Zachary R., and Castillo, Jorge J.

Subjects
GENETIC mutation, MULTIPLE myeloma, WALDENSTROM'S macroglobulinemia, PLASMA cell diseases, IMMUNOLOGIC diseases
Abstract

Summary: MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM‐secreting B‐cell malignancies. Diagnostic discrimination can be difficult among suspected wild‐type MYD88 (MYD88WT) WM cases. We systematically reviewed the clinical, pathological and laboratory studies for 64 suspected MYD88WT WM patients. World Health Organization and WM consensus guidelines were used to establish clinicopathological diagnosis. Up to 30% of suspected MYD88WT WM cases had an alternative clinicopathological diagnosis, including IgM multiple myeloma. The estimated 10‐year survival was 73% (95% confidence interval [CI] 52–86%) for MYD88WTversus 90% (95% CI 82–95%) for mutated (MYD88MUT) WM patients (Log‐rank P < 0·001). Multivariate analysis only showed MYD88 mutation status (P < 0·001) as a significant determinant for overall survival. Diffuse large B‐cell lymphoma (DLBCL) was diagnosed in 7 (15·2%) and 2 (0·76%) of MYD88WT and MYD88MUT patients, respectively (Odds ratio 23·3; 95% CI 4·2–233·8; P < 0·001). Overall survival was shorter among MYD88WT patients with an associated DLBCL event (Log‐rank P = 0·08). The findings show that among suspected MYD88WT WM cases, an alternative clinicopathological diagnosis is common and can impact clinical care. WM patients with MYD88WT disease have a high incidence of associated DLBCL events and significantly shorter survival versus those with MYD88MUT disease. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

21. Predictors of response and survival in a large cohort of 319 Waldenström macroglobulinemia patients treated with ibrutinib monotherapy

Author

Castillo, Jorge J., Sarosiek, Shayna R., Gustine, Joshua N., Flynn, Catherine A., Leventoff, Carly R., White, Timothy P., Meid, Kirsten, Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Hunter, Zachary R., Patterson, Christopher J., Branagan, Andrew R., and Treon, Steven P.

Abstract

Bruton tyrosine kinase (BTK) inhibitors are the only FDA-approved treatments for Waldenström macroglobulinemia (WM). Factors prognostic of survival and predictive of response to BTK inhibitors remained to be clarified. We evaluated 319 patients with WM to identify predictive and prognostic factors on ibrutinib monotherapy. Logistic and Cox proportional-hazard regression models were fitted for response and survival. Multiple imputation analyses were used to address bias associated with missing data. Major (partial response or better) and deep responses (very good partial response or better) were attained in 78% and 28% of patients. CXCR4mutations were associated with lower odds of major (OR 0.2, 95% CI 0.1-0.5; p<0.001) and deep response (OR 0.3, 95% CI 0.2-0.6; p=0.001). CXCR4mutations (HR 2.0, 95% CI 1.2-3.4; p=0.01) and platelet count 100 K/uL or less (HR 2.5, 95% CI 1.3-4.9; p=0.007) were associated with worse progression-free survival (PFS). We proposed a scoring system using these two factors. The median PFS for patients with zero, one and two risk factors were not reached, 5 years and 3 years (p<0.001). Patients with two risk factors had HR 2.2 (95% CI 1.3-3.8; p=0.004) compared with one factor, and patients with one factor had HR 2.3 (95% CI 1.1-5.1; p=0.03) compared with zero factors. Age 65 years or older was the only factor associated with overall survival (HR 3.2, 95% CI 1.4-7.0; p=0.005). Multiple imputation analyses did not alter our results. Our study confirms the predictive and prognostic value of CXCR4mutations in patients with WM treated with ibrutinib monotherapy.

Published
2021
Full Text
View/download PDF

22. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.

Author

Garcia-Sanz R, Varettoni M, Jiménez C, Ferrero S, Poulain S, San-Miguel JF, Guerrera ML, Drandi D, Bagratuni T, McMaster M, Roccaro AM, Roos-Weil D, Leiba M, Li Y, Qiu L, Hou J, De Larrea CF, Castillo JJ, Dimopoulos M, Owen RG, Treon SP, and Hunter ZR

Subjects
Humans, Myeloid Differentiation Factor 88 genetics, In Situ Hybridization, Fluorescence, Mutation, Waldenstrom Macroglobulinemia diagnosis, Waldenstrom Macroglobulinemia genetics, Waldenstrom Macroglobulinemia therapy
Abstract

Apart from the MYD88 L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3 (CP3) of the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring. Key recommendations from IWWM-11 CP3 included: (1) molecular studies are warranted for patients in whom therapy is going to be started; such studies should also be done in those whose bone marrow (BM) material is sampled based on clinical issues; (2) molecular studies considered essential for these situations are those that clarify the status of 6q and 17p chromosomes, and MYD88, CXCR4, and TP53 genes. These tests in other situations, and/or other tests, are considered optional; (3) independently of the use of more sensitive and/or specific techniques, the minimum requirements are allele specific polymerase chain reaction for MYD88 L265P and CXCR4 S338X using whole BM, and fluorescence in situ hybridization for 6q and 17p and sequencing for CXCR4 and TP53 using CD19+ enriched BM; (4) these requirements refer to all patients; therefore, sample should be sent to specialized centers., (Copyright © 2023 Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results